AndroGel Pharmacokinetics: How Testosterone Gel Is Absorbed, Distributed, Metabolized, and Excreted

How AndroGel Delivers Testosterone Through the Skin

AndroGel works by creating a drug reservoir in the stratum corneum after topical application. Testosterone molecules diffuse from this reservoir through the epidermis and dermis into the capillary bed, entering systemic circulation without first-pass hepatic destruction. This transdermal route is the pharmacological reason gel formulations exist for testosterone replacement.

The stratum corneum acts as the rate-limiting barrier. Testosterone, a lipophilic steroid with a molecular weight of 288 Da, crosses this barrier via passive diffusion along a concentration gradient [1]. The gel vehicle (a hydroalcoholic base) enhances permeation by temporarily disrupting lipid packing in the intercellular spaces of the stratum corneum. Ethanol evaporates within minutes of application, leaving a thin testosterone film on the skin surface that continues to release drug over several hours.

The FDA-approved prescribing information for AndroGel 1.62% reports that approximately 10% of the applied testosterone dose becomes systemically bioavailable [2]. For a 40.5 mg daily dose of AndroGel 1.62%, this translates to roughly 4 mg of testosterone entering the bloodstream. That number aligns with the normal daily endogenous production rate of 3 to 10 mg in eugonadal men, as cited by the Endocrine Society's 2018 clinical practice guideline [3].

Application site matters. A pharmacokinetic comparison within the AndroGel 1.62% development program found that application to the upper arms and shoulders produced 30% higher area-under-the-curve (AUC) values than application to the abdomen [2]. The Endocrine Society guideline recommends applying testosterone gel to clean, dry, intact skin on the shoulders or upper arms to optimize absorption [3].

Absorption Kinetics and Time to Steady State

After a single application of AndroGel 1%, serum testosterone concentrations begin rising within 30 minutes, reach peak levels (Cmax) at approximately 2 to 4 hours, and then plateau before the next dose [4]. The reservoir effect in the stratum corneum sustains absorption for the full 24-hour dosing interval.

Steady state arrives fast. The AndroGel 1% key trial by Swerdloff et al. (N=227) demonstrated that 87% of men treated with 50 mg or 100 mg daily achieved serum testosterone in the normal range (300 to 1 to 000 ng/dL) within 24 hours of the first dose, with full pharmacokinetic steady state confirmed by day 30 [4]. For AndroGel 1.62%, the FDA label reports steady-state AUC values of 7 to 520 ng·h/dL at the 40.5 mg dose and 14 to 400 ng·h/dL at the 81 mg dose [2].

One pharmacokinetic detail often missed in clinical practice: absorption continues for up to 6 hours after application. The prescribing information advises patients to wait at least 2 hours (for 1.62%) or 5 to 6 hours (for 1%) before showering. Washing the site at 1 hour post-application reduces bioavailability by up to 50%, according to a wash-off substudy included in the original NDA submission [2].

The T-Trials (N=790 men aged 65 and older) confirmed that daily topical testosterone application raised serum testosterone from a mean baseline of 232 ng/dL into the mid-normal range (averaging 500 to 600 ng/dL) within 1 month, sustaining those levels over 12 months of treatment [5]. Dr. Peter Snyder, principal investigator of the T-Trials and professor at the University of Pennsylvania, stated: "The consistency of serum testosterone levels achieved with daily gel application was comparable to what we see with the physiologic circadian rhythm in younger men" [5].

Distribution: Protein Binding and Tissue Partitioning

Testosterone entering the bloodstream from the dermal capillary bed distributes according to the same binding profile as endogenously produced testosterone. Approximately 98% circulates bound to plasma proteins. Free testosterone, the biologically active fraction, accounts for only 1 to 2% of total circulating testosterone.

The binding hierarchy is specific. Sex hormone-binding globulin (SHBG) binds roughly 40% of circulating testosterone with high affinity (Kd ~1 nmol/L). Albumin binds approximately 58% with much lower affinity (Kd ~100 nmol/L) [6]. The albumin-bound fraction dissociates readily at the capillary level, making it "bioavailable" alongside free testosterone. This is why clinicians measure both total testosterone and free testosterone (or calculate bioavailable testosterone) when assessing therapeutic adequacy.

Tissue distribution follows androgen receptor density. Testosterone concentrates in reproductive tissues (prostate, seminal vesicles, epididymis), skeletal muscle, bone, skin, and the hypothalamic-pituitary axis. The volume of distribution is not precisely defined for exogenous transdermal testosterone because it mixes with endogenous production, but endogenous testosterone has a reported apparent volume of distribution of approximately 80 to 100 L [6].

One clinically relevant distribution consideration is skin-to-skin transfer. The AndroGel prescribing information includes a dedicated pharmacokinetic substudy showing that direct skin contact with an untreated partner 2 hours after gel application can raise the partner's serum testosterone by 2- to 3-fold above baseline [2]. This prompted the FDA boxed warning regarding secondary exposure, particularly to children and women.

Metabolism: Hepatic Pathways and DHT Conversion

Testosterone undergoes extensive metabolism through two primary enzymatic pathways. The first and most clinically significant is reduction by 5-alpha-reductase, which converts testosterone to dihydrotestosterone (DHT). The second is aromatization by cytochrome P450 aromatase (CYP19A1), which converts testosterone to estradiol.

5-alpha-reductase exists in two isoforms. Type 1 predominates in skin and liver. Type 2 predominates in prostate, seminal vesicles, and hair follicles [7]. Because transdermal testosterone is absorbed through the skin, it encounters type 1 5-alpha-reductase during its passage through the dermis before reaching systemic circulation. This "first-pass skin metabolism" explains a well-documented pharmacokinetic finding: topical testosterone produces a disproportionately higher DHT-to-testosterone ratio compared to intramuscular injections.

The Swerdloff et al. pharmacokinetic study reported DHT-to-testosterone ratios of 0.27 to 0.33 in men using AndroGel 1%, compared to a normal physiologic ratio of approximately 0.10 to 0.15 [4]. The Endocrine Society's 2018 guideline, authored by Bhasin et al., notes: "Transdermal testosterone formulations produce higher DHT concentrations relative to serum testosterone than injectable formulations, though the clinical significance of this difference remains uncertain after more than two decades of use" [3].

After reaching the liver via systemic circulation, testosterone is further metabolized by hepatic oxidation (CYP3A4), reduction, and hydroxylation. The major hepatic metabolites include androsterone, etiocholanolone, and androstanediol. These are then conjugated with glucuronic acid or sulfate to form water-soluble metabolites ready for renal excretion [6].

A third metabolic pathway, aromatization to estradiol via CYP19A1 in adipose tissue and brain, accounts for a smaller fraction of testosterone metabolism but carries clinical significance. In men with obesity, increased aromatase activity can shunt more testosterone toward estradiol, potentially attenuating the androgenic response to replacement therapy. The 2018 Endocrine Society guideline recommends monitoring estradiol in men with BMI >35 who have suboptimal responses to testosterone therapy [3].

Excretion and Elimination Half-Life

Testosterone and its metabolites are eliminated primarily through the kidneys. Approximately 90% of a testosterone dose is excreted in urine as glucuronide and sulfate conjugates of androsterone, etiocholanolone, and other reduced metabolites. The remaining 6% appears in feces, largely as unconjugated steroid [6].

The elimination kinetics of transdermal testosterone are unique. Because the stratum corneum reservoir continues to release testosterone into circulation for hours after application, the apparent elimination half-life measured after gel removal is much longer than the true plasma half-life of free testosterone (10 to 100 minutes). After discontinuing daily gel application, serum testosterone returns to baseline hypogonadal levels within 48 to 72 hours in most patients [2]. This rapid washout is both a clinical advantage (for safety) and a clinical limitation (missed doses cause prompt declines).

A pharmacokinetic modeling study published in the Journal of Clinical Endocrinology & Metabolism estimated the effective absorption half-life from the skin depot at approximately 2 to 4 hours, with the terminal elimination phase governed by the skin reservoir depletion rate rather than the intrinsic clearance of testosterone itself [8]. The metabolic clearance rate of testosterone in adult men ranges from 580 to 980 L/day [6].

For clinicians adjusting doses, this elimination profile means that trough levels drawn immediately before the next daily application most accurately reflect therapeutic adequacy. The Endocrine Society recommends checking serum testosterone 2 to 8 hours after application for peak assessment, or immediately pre-dose for trough assessment, beginning 1 to 2 weeks after any dose change [3].

Dose-Response Relationship and Therapeutic Monitoring

The dose-proportionality of AndroGel has been well characterized. For the 1.62% formulation, increasing the daily dose from 20.25 mg to 40.5 mg to 60.75 mg to 81 mg produces a roughly linear increase in steady-state AUC and Cavg values [2]. The 40.5 mg starting dose of AndroGel 1.62% produces a mean Cavg of approximately 450 ng/dL, while the 81 mg maximum dose produces a mean Cavg near 750 ng/dL.

A dose-finding analysis from the original AndroGel 1% program (N=227) reported the following steady-state Cavg values by dose: 50 mg daily yielded 555 ± 225 ng/dL, 75 mg daily yielded 601 ± 226 ng/dL, and 100 mg daily yielded 713 ± 209 ng/dL [4]. The wide standard deviations reflect substantial inter-individual variability in transdermal absorption, a pharmacokinetic property driven by differences in skin thickness, vascularity, body composition, and application technique.

The T-Trials provided the largest and longest dataset on topical testosterone efficacy in older men. Among 790 men aged 65 years and older with serum testosterone <275 ng/dL, daily testosterone gel application (with dose titration to a target of 500 to 800 ng/dL) produced mean testosterone levels of 540 ng/dL at month 3 and 480 ng/dL at month 12 [5]. The modest decline over time may reflect changes in adherence, application technique, or skin characteristics with prolonged use.

Because of the high inter-patient variability, the Endocrine Society recommends titrating dose based on serum testosterone levels measured at steady state rather than relying on fixed-dose protocols [3]. The target range is 450 to 600 ng/dL for most men, though the specific target depends on symptom response and the clinical context of treatment.

Factors That Alter Absorption and Pharmacokinetic Variability

Several patient-level and environmental factors modify the pharmacokinetics of transdermal testosterone. Understanding these variables helps clinicians troubleshoot suboptimal responses and avoid supratherapeutic levels.

Skin condition is the most significant variable. Damaged, inflamed, or sunburned skin absorbs testosterone at higher and less predictable rates [2]. The prescribing information contraindicates application to broken skin. Body hair at the application site can reduce direct skin contact with the gel, though this effect has not been precisely quantified in published studies.

Sweating and physical activity within the first 2 to 6 hours after application can reduce absorption. A substudy in the AndroGel 1.62% NDA assessed the impact of exercise-induced perspiration at 1 hour post-application and found a 25 to 30% reduction in 24-hour AUC compared to sedentary conditions [2]. Patients who exercise in the morning should apply gel after their workout or choose an evening application time.

Sunscreen and dermal products create a barrier film. The FDA label advises against applying sunscreen or other topical products to the same area within 2 hours of gel application. Co-application of sunscreen at the time of testosterone gel application reduced testosterone AUC by approximately 15% in a crossover pharmacokinetic study [9].

Age-related changes in skin (thinning of the stratum corneum, reduced dermal blood flow) might be expected to alter absorption, but the T-Trials data in men aged 65 and older showed no clinically meaningful age-related pharmacokinetic differences compared to younger populations studied in earlier trials [5].

Drug interactions affecting metabolism are relatively limited for topical testosterone. CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) can increase serum testosterone levels by slowing hepatic clearance, though the magnitude of this effect is smaller than with oral testosterone formulations that undergo first-pass hepatic metabolism [6]. Insulin and oral anticoagulants may require dose adjustments during testosterone therapy, as testosterone can increase insulin sensitivity and potentiate warfarin's anticoagulant effect [2].